JPRN-UMIN000005199已完成2 期
Phase II study of Bevacizumab with SOX (S-1 plus L-OHP) as second-line therapy in metastatic colorectal cancer - Phase II study of Bevacizumab with SOX (S-1 plus L-OHP) as second-line therapy in metastatic colorectal cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) History of severe allergy (2) Active double cancer (3) Severe infectious disease (4) Peripheral neuropathy (5) Uncontrolled hypertention (6) Sever comorbidity(interstitial lung disease or pulmonary fibrosis, heart failure, renal failure, liver failure, etc) (7) Massive pleural or abdominal effusion (8) Patient with the diarrhea (9) Symptomatic brain metastases (10) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test (11) Severe mental disorder (12) Systemic administration of corticosteroids (13) Uric protein 2+ (14) Prior radiotherapy for primary and metastases tumors (15) Thrombosis, cerebral infraction, cardiac infraction or pulmonary infraction within 6 months (16) Patients who underwent surgery within 4 weeks (17) Systemic administration of antiplatelet drug (18) Patients with known bleeding disorders or clotting disorder (19) Previous history of adjuvant chemotherapy with L-OHP (20)Any other cases who are regarded as inadequate for study enrollmet by investigators
研究者
相似试验
招募中
2 期
Randomized Phase II study of Bevacizumab with SOX versus Bevacizumab with XELOX as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1 and CPT-11Metastatic colorectal cancerJPRN-UMIN000006911Tsuchiura kyodo general hospital60
招募中
2 期
Multicenter Phese II Study of SOX plus Bevacizumab Therapy with Oxaliplatin Stop-and-Go Strategy and Oral S-1 plus Bevacizumab Maintenance Therapy in Advanced Colorectal CancerCnresectable metastatic or recurrent colorectal cancerJPRN-UMIN000011680Chubu Clinical Oncology Group40
已完成
2 期
A Phase II trial of SOX plus bevacizumab or cetuximab as neoadjuvant chemotherapy in patients with locally advanced rectal cancer (OITA-trial II)locally advanced rectal cancerJPRN-UMIN000012856Department of Gastroenterological and Pediatric Surgery, Oita University faculty of medicine70
已完成
2 期
Phase II study of S-1 plus Bevacizumab combination chemotherapy for patients with non-small-cell lung cancer.lung cancerJPRN-UMIN000004677Shinshu University thoracic surgery55
已完成
2 期
Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancerColorectal cancerJPRN-UMIN000009083Aichi Cancer Center Hospital, Department of Clinical Oncology30